Comparison of selected standard pre-transplant salvage regimens for Hodgkin’s lymphoma.
| Regimen . | Ref. . | # of Pts. . | RR (CR) . | Toxic Deaths . |
|---|---|---|---|---|
| Abbreviations: RR, response ratio; CR, complete response. | ||||
| Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) | 1 | 144 | 81% (27%) | 5% |
| Mini-BEAM (carmustine, etoposide, cytarabine, melphalan) | 5 | 55 | 82% (49%) | 2% |
| ICE (ifosfamide, carboplatin, etoposide) | 6 | 65 | 88% (26%) | 0% |
| ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) | 8 | 22 | 73% (41%) | 5% |
| ASHAP (doxorubicin, methylprednisolone, cytarabine, cisplatin) | 9 | 56 | 70% (34%) | 0% |
| GVD (gemcitabine, vinorelbine, liposomal doxorubicin) | 14 | 50 | 60% (20%) | 0% |
| GDP (gemcitabine, dexamethasone, cisplatin) | 12 | 23 | 69% (17%) | 0% |
| Regimen . | Ref. . | # of Pts. . | RR (CR) . | Toxic Deaths . |
|---|---|---|---|---|
| Abbreviations: RR, response ratio; CR, complete response. | ||||
| Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) | 1 | 144 | 81% (27%) | 5% |
| Mini-BEAM (carmustine, etoposide, cytarabine, melphalan) | 5 | 55 | 82% (49%) | 2% |
| ICE (ifosfamide, carboplatin, etoposide) | 6 | 65 | 88% (26%) | 0% |
| ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) | 8 | 22 | 73% (41%) | 5% |
| ASHAP (doxorubicin, methylprednisolone, cytarabine, cisplatin) | 9 | 56 | 70% (34%) | 0% |
| GVD (gemcitabine, vinorelbine, liposomal doxorubicin) | 14 | 50 | 60% (20%) | 0% |
| GDP (gemcitabine, dexamethasone, cisplatin) | 12 | 23 | 69% (17%) | 0% |